hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06261112 id: B.30.2.ATA.01.11/285 briefTitle: The Effect of Using a Kaleidoscope on Fear and Pain in Children overallStatus: RECRUITING date: 2022-05-07 date: 2024-05-01 date: 2024-05-01 date: 2024-02-15 date: 2024-02-15 name: Mihriban Culha class: OTHER briefSummary: The research was conducted in randomized controlled experimental type between May 2022 and December2023. The universe of the research consisted of children and their parents who were diagnosed with a fracture, applied to the Orthopedic outpatient clinic and Emergency department of the Erzurum Ataturk University Health Research and Application Center and referred to the Orthopedic clinic, and decided to undergo a cast procedure for treatment. The sample of the research consisted of a total of 70 children and their parents, including 35 control groups and 35 kaleidoscope groups, who met the research criteria from this universe. The children in the kaleidoscope group were shown the kaleidoscope. No intervention other than routine application was applied to the control group. "Introductory Information Form", "Wong-Baker Facial Expressions Rating Scale and Child Fear Scale were used in the collection of data. conditions: Fracture; Complication Orthopedic Procedure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assigment primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: single /investigatör) whoMasked: INVESTIGATOR count: 70 type: ESTIMATED name: kaleidescope measure: Child Fear Scale (CFS) measure: Facial Expressions Rating Scale sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Ataturk University status: RECRUITING city: Erzurum zip: 25240 country: Turkey name: Mihriban ÇULHA role: CONTACT phone: 05070926243 email: mihriban2560@outlook.com lat: 39.90861 lon: 41.27694 hasResults: False
nctId: NCT06261099 id: 037 briefTitle: Telerehabilitation-Based Early Upper Extremity Training in Stroke Patients overallStatus: RECRUITING date: 2024-02-08 date: 2025-02-27 date: 2025-11-27 date: 2024-02-15 date: 2024-02-15 name: Suleyman Demirel University class: OTHER briefSummary: Telerehabilitation method, which is an alternative to face-to-face rehabilitation practices for stroke patients who need intensive, regular and long-term rehabilitation in the early period, has been popularly used in recent years. Telerehabilitation is a practice in which the patient participates in the treatment via digital media without the need for the patient to come to the clinic. conditions: Stroke, Acute studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: prospective double-blind, randomized controlled trial primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Sealed envelopes will be prepared in advance for randomization and will be marked with numbers 1 and 2, indicating whether they are a study group or a control group. Randomization will be done by a third party unaware of the study content. Randomization order tracking will be done with sequentially numbered containers. Patients participating in the study will be blinded to which treatment group they will be included in. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: control + working group measure: Mini Mental Test measure: Fugl Meyer Motor Function Scale measure: Laser-pointer Assisted Angle Reproduction Test measure: Modified Barthel Index measure: Reaching Performance Scale sex: ALL minimumAge: 30 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Güler Ertuğrul status: RECRUITING city: Kocaeli state: İ̇zmi̇t country: Turkey name: GÜLER ERTUĞRUL role: CONTACT phone: +90 531 950 05 90 email: gertugrul004@gmail.com lat: 39.62497 lon: 27.51145 facility: Suleyman Demirel University status: RECRUITING city: Isparta state: Merkez country: Turkey name: MEHMET DURAY role: CONTACT phone: +90 506 473 11 65 email: mehmetduray@sdu.edu.tr lat: 37.76444 lon: 30.55222 hasResults: False
nctId: NCT06261086 id: soh-med-24-01-06MS briefTitle: Evaluation of Pyroptosis-related Indicators in the Pathogenesis of Vitiligo:Across-sectional Comparative Study overallStatus: NOT_YET_RECRUITING date: 2024-02-24 date: 2024-08-24 date: 2024-08-24 date: 2024-02-15 date: 2024-02-15 name: Sohag University class: OTHER briefSummary: Vitiligo is an acquired pigmentary disorder on skin and/or mucosae, which is characterized by death of melanocytes (MCs), affecting 0.5%-2% of the population worldwide (1). It doesn't affect the health of patients but it has marked social pressure and greatly interfere with their quality of life (2,3). It presents with well circumscribed milky white patches that occur secondary to destruction of melanocyte, it may appear at any age and affect both sexes equally.
Clinically, several types of vitiligo are distinguished according to the distribution of the achromic lesions. One or more lesions in a dermatomal pattern are characteristic for segmental vitiligo (SV) while this segmental distribution is absent in non-segmental vitiligo (NSV). The latter variety includes both the focal type and the generalized type (5). Numerous previous studies tried to illustrate the pathogenesis behind the disease, but the exact pathophysiology is still not fully understood. It is a multifactorial disease. Factors include, neural theory, oxidative stress theory, autoimmune hypothesis, intrinsic theory, melanocytorrhagy hypothesis (6). Many theories tried to explain the mechanisms of MC destruction in vitiligo. Apoptosis is one of the most widely studied cell death pathways. In addition, the other two forms of cell death, conventional necrosis and autophagy seem to be involved in the death of vitiligo MCs under certain situations. Moreover, new types of regulated cell death including necroptosis, pyroptosis, and ferroptosis may also participate in the pathogenesis (7). Pyroptosis is a highly inflammatory form of necrosis cell death NCD regulated mainly by caspase-1, which is initiated following large supramolecular complex ermed inflammasome activation (8). The inflammasome-activated Caspases then cleave the pyroptosis-inducing protein Gasdermin D (GSDMD), which forms a pore in the plasma membrane and causes cell lysis as well as the secretion of IL-1β typically (9). Another study suggests that inflammasome activation could be a useful marker for assessing disease progression of vitiligo (10). However, the link between vitiligo and inflammasome activation is still unclear. The inflammasome regulates cell death and inflammation via activation of caspase-1 (11). The activation of caspase-1 promotes the secretion of proinflammatory cytokines IL-1β and IL-18, as well as the initiation of pyroptosis (12). So, evaluation of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18) may help understanding the obscure inflammasome pathway involvement in the pathogenesis of Vitiligo. conditions: Vitiligo studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 90 type: ESTIMATED name: evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18) measure: GASDM-D measure: IL 1β measure: IL-18 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06261073 id: Soh-Med-24-01-08MS briefTitle: Evaluation of Serum and Tissue Cathepsin L in Non-segmental Vitiligo Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-03-01 date: 2025-03-01 date: 2024-02-15 date: 2024-02-15 name: Sohag University class: OTHER briefSummary: Introduction Vitiligo is an autoimmune disease of the skin that targets pigment producing melanocytes and results in patches of depigmentation that are visible as white spots (Frisoli et al., 2020) Vitiligo is a relatively common acquired pigmentation disorder that can cause significant psychological stress (Leung AKC et al., 2021). The disease affects both genders equally, it can appear at any age, and the average age of onset is somewhat variable in different geographic (Majumder et al, 1993), with an estimated prevalence of 0.5-2% of the population in both adults and children worldwide (Krüger et al, 2012).
Vitiligo results in white macules and patches on the body. Initial lesions occur most frequently on the hands, forearms, feet, and face, favoring a periocular or perioral distribution (Ahmed jan N et al., 2023). Vitiligo lesions are classified into 2 major categories: segmental vitiligo (SV) and non-segmental vitiligo (NSV) (Relke et al ., 2019). Segmental vitiligo is characterized by its early onset, rapid stabilization, and unilateral distribution (Van Geel et al., 2017). Non-segmental vitiligo comprises of generalized (vitiligo vulgaris), acrofacial, mucosal (multifocal), and universal vitiligo (Kovacevic et al., 2016). Non-segmental vitiligo (NSV) is the most common form of vitiligo (Benzekri et al., 2013). Multiple mechanisms are involved in melanocyte disappearance, namely genetic predisposition, environmental triggers, metabolic abnormalities, impaired renewal, and altered inflammatory and immune responses (Boniface K et al ., 2018).
The results of some studies indicate a frequent association of vitiligo with autoimmune diseases. A number of studies have established a higher prevalence of autoimmune endocrine diseases in women, as well as in non-segmental vitiligo patients and in cases of family history of vitiligo and/or other autoimmune diseases. In addition, it was shown that the prevalence of endocrine diseases increases with increasing area of depigmentation (Troshina EA et al., 2020). Autoimmunity in vitiligo is driven by the IFN-γ-CXCL10 cytokine signaling pathway. Activated melanocyte-specific CD8+ T cells secrete IFN-γ, which signals through the IFN-γ receptor (IFN-γR) to activate JAK1/2 and STAT1. This induces the production of CXCL9 and CXCL10, which signal through their receptor CXCR3 to recruit more auto-reactive T cells to the epidermis, resulting in widespread melanocyte destruction (Harris JE et al., 2017).
The lysosomal cysteine proteinases of the papain family are involved in lysosomal bulk proteolysis, major histocompatibility complex class II-mediated antigen presentation, pro-hormone processing, and extracellular matrix remodeling. conditions: Vitiligo studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 40 type: ESTIMATED name: blood sample and tissue biopsy measure: Cathepsin L sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT hasResults: False
nctId: NCT06261060 id: 2023-0918 id: NCI-2024-01333 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder overallStatus: NOT_YET_RECRUITING date: 2024-08-31 date: 2026-06-11 date: 2028-06-11 date: 2024-02-15 date: 2024-03-07 name: M.D. Anderson Cancer Center class: OTHER briefSummary: To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD. conditions: Familial Platelet Disorder conditions: Hematopoietic studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: Sirolimus measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Courtney DiNardo, MD role: CONTACT phone: 713-794-1141 email: cdinardo@mdanderson.org name: Courtney DiNardo, MD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06261047 id: SDZLEC2023-389-02 briefTitle: Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer overallStatus: RECRUITING date: 2024-01-01 date: 2026-01-01 date: 2026-01-01 date: 2024-02-15 date: 2024-02-15 name: Shandong Cancer Hospital and Institute class: OTHER briefSummary: Recent years have seen significant advancements in the treatment landscape of advanced hepatocellular carcinoma (HCC), with the emergence of targeted and immunotherapy strategies reshaping first-line therapy. Sorafenib, a multi-targeted tyrosine kinase inhibitor, initially set the standard, followed by approvals for lenvatinib, regorafenib, cabozantinib, and ramucirumab. Immunotherapy, particularly combinations like atezolizumab with bevacizumab, has shown superior efficacy over sorafenib. Despite these advances, second-line therapies offer limited progression-free survival (mPFS: 2-3 months), necessitating new approaches. Radiotherapy, bolstered by technological advancements, has shown promise. Techniques like stereotactic body radiotherapy (SBRT) combined with PD-1 inhibitors achieve significant response rates and survival benefits. Combining radiotherapy with targeted immunotherapy has also demonstrated improved outcomes. Radiotherapy, especially in oligometastatic HCC, is increasingly favored due to its ability to enhance local control without increasing toxicity. These developments underscore the evolving landscape of HCC treatment towards personalized and multimodal approaches. conditions: Hepatocellular Carcinoma conditions: Radiotherapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 36 type: ESTIMATED name: radiotherapy measure: Progression free survival measure: Overall response rate measure: Overall survial measure: Disease control rate measure: Duration of control sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Jinbo Yue status: RECRUITING city: Jinan state: Shandong zip: 250000 country: China name: jinbo yue role: CONTACT phone: +86053167626442 email: yuejinbo@hotmail.com lat: 36.66833 lon: 116.99722 hasResults: False
nctId: NCT06261034 id: 23-008765 id: 8K12AR084222-15 type: NIH link: https://reporter.nih.gov/quickSearch/8K12AR084222-15 briefTitle: A Study of Sex Differences in Neurocirculatory Control overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-03 date: 2027-03 date: 2024-02-15 date: 2024-04-10 name: Mayo Clinic class: OTHER name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) briefSummary: The purpose of this study is to investigate potential sex differences in neurocirculatory control of blood pressure in patients with untreated obstructive sleep apnea (OSA). conditions: Obstructive Sleep Apnea studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED measure: Blood pressure measure: Arterial stiffness measure: Endothelial function measure: Sympathetic nerve burst frequency measure: Sympathetic nerve burst incidence measure: Sympathetic nerve burst amplitude (AU) measure: Total muscle sympathetic nerve activity (MSNA) measure: Cerebral autoregulation measure: Sympathetic action potentials per burst measure: Sympathetic action potential clusters per burst measure: Sympathetic action potential conduction latency of each cluster measure: Immune function measure: Urinary Extracellular Vesicle Presence and Content measure: Plasma Extracellular Vesicle Presence and Content sex: ALL minimumAge: 20 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Rochester city: Rochester state: Minnesota zip: 55905 country: United States name: Joshua Bock, PhD role: CONTACT phone: 507-422-0768 email: bock.joshua@mayo.edu name: Ian Greenlund, PhD role: CONTACT phone: (507) 422-3411 email: Greenlund.Ian@mayo.edu name: Virend Somers, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 44.02163 lon: -92.4699 hasResults: False
nctId: NCT06261021 id: INNO-6051 briefTitle: Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus overallStatus: RECRUITING date: 2024-04-19 date: 2025-02 date: 2025-02 date: 2024-02-15 date: 2024-04-25 name: Innovaderm Research Inc. class: OTHER briefSummary: This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus. conditions: Discoid Lupus Erythematosus studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Intra-individual primaryPurpose: TREATMENT masking: SINGLE maskingDescription: This study will be single-blinded. Only the efficacy assessor will be blinded in this study (for subjects with randomized areas). The assessor will only assess efficacy and will not have any other interactions with the subject. whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Ruxolitinib 1.5% cream name: Application without occlusion in Area 1 name: Application under occlusion at night in Area 2 name: Application under occlusion at night in Area 1 name: Application without occlusion in Area 2 measure: Change from baseline in target lesion CLASI-A score measure: Change from baseline in target lesion CLASI-A score measure: Proportion of subjects with an erythema score of 0 (absent) measure: Change from baseline in target lesion SADDLE-A measure: Proportion of subjects with a target lesion CLA-IGA score of 0 (clear) or 1 (almost clear) measure: Dermatology Life Quality Index (DLQI) measure: Cutaneous Lupus Erythematosus Quality of Life (CLEQol) measure: Numeric Rating Scale(NRS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Innovaderm Research Inc. status: RECRUITING city: Montréal state: Quebec zip: H2X 2V1 country: Canada name: Fareheen Chowdhury, MSc role: CONTACT phone: 514-521-4285 phoneExt: 341 email: fchowdhury@innovaderm.com name: Robert Bissonnette role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06261008 id: 2023.553 briefTitle: Interactive Telehealth Intervention to Increase Longitudinal Adherence to Repeat Faecal Immunochemical Test Screening overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-03-26 date: 2026-06-26 date: 2024-02-15 date: 2024-02-16 name: Chinese University of Hong Kong class: OTHER briefSummary: In Hong Kong, Colorectal cancer ranks second in both cancer incidence and mortality. The government-subsidized population-based CRC screening program (the Program) was launched for asymptomatic individuals aged 50-75 years to undergo biennial FIT screenings. A subsidized follow-up colonoscopy is offered to participants with positive FIT results. Participants are advised to repeat the FIT screening 2 years after receiving a negative result. An automated noninteractive short message service (SMS) text reminder, used by the Program as standard care (SC), is delivered to participants who are due for repeat FIT. According to unpublished data, despite SC, only 34% of participants adhere to biennial repeat FIT in the CRC screening program. Nonadherence to repeat FIT screening is caused by forgetfulness and is associated with an individual's psychological health behaviour. conditions: CRC, Colorectal Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Patient will be randomized into either standard care or telehealth intervention group primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE maskingDescription: There will no masking count: 370 type: ESTIMATED name: TI group measure: adherence rate measure: the number of days to repeat FIT measure: costs incurred in each study arm measure: uptake rate in positive FIT measure: detection rate in positive FIT measure: qualitative factors associated with repeat FIT adherence sex: ALL minimumAge: 50 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre of Digestive Health, Prince of Wales Hospital city: Hong Kong country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06260995 id: Ref: 230603 briefTitle: The Role of Intermediaries in Connecting Individuals to Local Physical Activity - Study Protocol overallStatus: RECRUITING date: 2023-09-01 date: 2024-05-31 date: 2024-06-30 date: 2024-02-15 date: 2024-02-21 name: University of Dublin, Trinity College class: OTHER briefSummary: Intermediaries help people to connect to community-based services and supports, including physical activity and exercise groups (physical activities). They do this by acting as a link person. After receiving a referral or self-referral, they conduct an assessment, connect people to services in the community, and follow-up with people over time.
This project will investigate if connecting to physical activities through an intermediary can improve health and wellbeing. It will also investigate people's experiences of working with an intermediary. This project is a pilot feasibility study, which means the investigators are evaluating the measures used and the way the trial is designed to see if they are suitable for a larger study in the future. conditions: Physical Inactivity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Social Prescribing Link Worker Intermediary Intervention name: Local Sports Partnership Community Development Officer Intervention measure: International Physical Activity Questionnaire - Short Form measure: Self-Efficacy for Exercise Scale measure: Short Warwick Edinburgh Mental Well-being Scale measure: Demographics and Health Status measure: Semi-structured Interviews - Intervention Participants measure: Overall Acceptability of the Intervention measure: Gatekeeper Recruitment Logs measure: Semi-structured Interviews - Gatekeepers sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Dublin, Trinity College Dublin status: RECRUITING city: Dublin 8 zip: D08 W9RT country: Ireland name: Megan O'Grady role: CONTACT phone: 018963613 email: ogradyme@tcd.ie lat: 53.33306 lon: -6.24889 hasResults: False
nctId: NCT06260982 id: 2021PI148 briefTitle: Cognitive Disorders in Hereditary Spastic Paraplegia Type 4 acronym: SPG-TEP overallStatus: RECRUITING date: 2022-01-01 date: 2025-01 date: 2025-01-02 date: 2024-02-15 date: 2024-02-15 name: Central Hospital, Nancy, France class: OTHER briefSummary: Hereditary spastic paraplegia type 4 is the most frequent mutation of hereditary spastic paraplegias. It is commonly described as pure, with progressive weakness of the lower limbs, pyramidal syndrome and vesico-sphincter disorders. However, cognitive disorders have been reported for over 20 years, but remain poorly characterized. conditions: Spastic Paraplegia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: 18-FDG-PET measure: cognitive testing measure: Correlations between neuropsychological tests, clinical examination, PET and general data. measure: Genotype/Phenotype correlations sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Centre hospitalier régional universitaire status: RECRUITING city: Nancy zip: 54000 country: France name: Mathilde Renaud, MD, PhD role: CONTACT email: m.renaud2@chru-nancy.fr lat: 48.68439 lon: 6.18496 hasResults: False